The TOP trial is a parallel, single-blind, randomized, clinical superiority trial, N=1424 that sought to determine whether liberal versus restrictive transfusion strategy after major general and vascular surgery reduces adverse outcomes in high cardiac risk patients.

Sunil Rao, MD on the results.

ANGPTL3, presented at #AHA25 showed gene editing demonstrates few adverse events.

More from Dr. Harrington👇👇

Calling all coffee drinkers! Dr. Khan has good news from the DECAF trial presented at #AHA25. ☕☕☕

What is the potential clinical impact of the OPTIMA trial?

Here is one prediction. #AHA25

In patients with AF who are stable beyond one year of drug-eluding stent implantation NOAC monotherapy provides a simple and safe long-term therapy versus combination therapy.

📢 Adding evolocumab to lipid-lowering therapy significantly reduced the risk of a first major CV event in patients without prior heart attack or stroke.

#AHA25 ⬇️

The study demonstrates that DR10624 can lead to significant reductions in triglycerides with favorable safety and tolerability results.

Shayan Mohammadmoradi's, MS, PhD take on the data presented at #AHA25

PREVENT equation 🤝 cardiovascular kidney metabolic health

Learn more about CKM and PREVENT at #AHA25